Advanced Biomed战略调整，股价波动引关注

Strategic Progress - In December 2025, the company announced the sale of its 100% stake in its Hong Kong subsidiary, Advanced Biomed (HK) Limited, for a total consideration of $23,000, along with the transfer of related intellectual property [2] - The CEO, Dr. Lu Yi, stated that this move aims to address changes in the regulatory environment, with future clinical trials to be concentrated through the Taiwan subsidiary [2] - This asset divestiture may impact the company's future business layout and operational focus [2] Stock and Financial Performance - In January 2026, the stock experienced significant volatility, with a notable drop of 5.95% on January 8, closing at $0.330 per share, accompanied by low trading volume of 1,277 shares and a fluctuation of 8.20% [3] - Financial reports for the same period indicated zero revenue, a net loss of $12,925.94, earnings per share of $0.00, and a price-to-earnings ratio of -2.14, reflecting a continued state of losses [3] - Future areas of interest include the execution progress of strategic adjustments, financial improvement, and overall dynamics in the life sciences industry [3]